前列环素类药物治疗肺动脉高压的研究进展  

Research progress in prostacyclins in treatment of pulmonary hypertension

作　　者：严明煜 吴小平 史胜楠 邓艳萍 韩卓君 张露 金沐阳 王培利[3] YAN Ming-yu;WU Xiao-ping;SHI Sheng-nan;DENG Yan-ping;HAN Zhuo-jun;ZHANG Lu;JIN Muyang;WANG Pei-li(Graduate School,Beijing University of Chinese Medicine,Beijing 100029,China;Graduate School,China Academy of Chinese Medical Sciences,Beijing 100700,China;National Clinical Research Center for Chinese Medicine Cardiology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)

机构地区：[1]北京中医药大学研究生院,北京100029 [2]中国中医科学院研究生院,北京100700 [3]中国中医科学院西苑医院心血管中心,北京100091

出　　处：《心脏杂志》2023年第1期99-101,110,共4页Chinese Heart Journal

基　　金：国家自然基金资助项目(81973681)。

摘　　要：肺动脉高压是肺高血压的一类,可危及生命。以肺动脉压力升高、肺血管阻力增加为主要特征,进而导致右心衰竭和死亡。前列环素信号通路是肺动脉高压重要的通路之一,除前列环素类似物和前列环素IP受体激动剂外,作用于血栓素A2的药物也正处于研究中。此外,还有更多新型治疗药物进入临床试验。本文通过对上述药物的简要介绍,以期为治疗肺动脉高压的治疗提供参考。Pulmonary arterial hypertension, a type of pulmonary hypertension, is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, leading to right heart failure and death. Prostacyclin signaling pathway is one of the important pathways of pulmonary arterial hypertension. In addition to prostacyclin analogs and prostacyclin IP receptor agonists, drugs acting on thromboxane A2 are also under study. In addition, more new therapeutic drugs are entering clinical trials.This paper briefly introduces the above drugs in order to provide reference for the treatment of pulmonary hypertension.

关 键 词：肺动脉高压 前列环素 治疗进展 

分 类 号：R544.1[医药卫生—心血管疾病]